Acute Myocardial Infarction
Conditions
Brief summary
Coronary heart disease is the single leading cause of death in the United States. In 2000, it was implicated in 681,000 deaths (1 in every 5 deaths). Myocardial infarction (MI) is the major cause of death in patients dying of coronary heart disease, with an estimated incidence of 1.1 million new and recurrent cases per year. It is well established that reperfusion is the most successful treatment for salvaging myocardium during acute infarction. However, despite such treatment, a substantial number of patients still remain at risk of developing large infarcts, with reduced left ventricular function and increased mortality. Therefore, adjunctive therapies that are designed to reduce ischemic metabolism and cellular injury pending successful reperfusion, or to protect myocytes against the undesired effects of reperfusion (reperfusion injury), should be beneficial in limiting infarct size. Mild hypothermia is one such potential therapy. This study has been designed to evaluate whether the adjunctive use of mild hypothermia further reduces the extent of heart damage caused by a heart attack.
Interventions
Sponsors
Radiant Medical
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The patient is greater than 18 years of age. * The patient must have symptoms consistent with acute myocardial infarction (i.e. chest pain, arm pain, etc.) and unresponsive to nitroglycerin, with symptoms beginning greater than 30 minutes but less than 6 hours prior to presentation. * Anterior wall MI with ST-segment elevation of ≥ 1 mm in two or more contiguous leads. * The patient is eligible for percutaneous coronary intervention (PCI). * The expected timing of the treatment pathway for the patient will allow for at least 30 minutes of cooling prior to PCI. * The patient or patient legal guardian is willing to provide written, informed consent to participate in this clinical study.
Exclusion criteria
* The patient has had a previous myocardial infarction within one month. * The patient is experiencing cardiogenic shock (systolic blood pressure \[SBP\] \<80 mmHg and non-responsive to fluids, or SBP \<100 mmHg with vasopressors, or requirement for an intra-aortic balloon pump \[IABP\]). * The patient has a known hypersensitivity to hypothermia, including a history of Raynaud's disease. * The patient has a known hypersensitivity or contraindication to aspirin, heparin, or sensitivity to contrast media, which cannot be adequately pre-medicated. * The patient has a known history of bleeding diathesis, coagulopathy, cryoglobulinemia or sickle cell anemia, or will refuse blood transfusions. * The patient has a height of \<1.5 m (4 feet 11 inches). * The patient is known to be pregnant or is expected to become pregnant prior to the 1 month follow-up. * The patient has a known hypersensitivity to buspirone hydrochloride or meperidine and/or has been treated with a monoamine oxidase inhibitor in the past 14 days. * Patient has a known history of severe hepatic or renal impairment, untreated hypothyroidism, Addison's disease, benign prostatic hypertrophy, or urethral stricture, that in the opinion of the physician would be incompatible with meperidine administration. * The patient has an inferior vena cava filter in place. * The patient has a pre-MI life expectancy of \<1 year due to underlying medical conditions or pre-existing co-morbidities. * The patient has a known, unresolved history of drug use or alcohol dependency, or lacks the ability to comprehend or follow instructions. * The patient is currently enrolled in the COOL MI trial or in another investigational drug or device trial that has not completed the primary endpoint or that clinically interferes with the COOL MI study endpoints. Note: For the purpose of this protocol, patients involved in extended follow-up trials for products that were investigational but are currently commercially available are not considered enrolled in an investigational trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in infarct size (single photon emission computed tomography [SPECT]) | — |
| Equivalent safety profile | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in infarct size (creatinine kinase MB [CK-MB], ST- Segment Resolution) | — |
| Improvement in left ventricular ejection fraction (LVEF) | — |
Countries
United States
Outcome results
None listed